Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMVT 1402

Next Previous
Drug Profile

IMVT 1402

Alternative Names: HL-161-ANS; IMVT-1402

Latest Information Update: 11 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator HanAll Biopharma
  • Developer HanAll Biopharma; Roivant Sciences
  • Class Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Neonatal Fc receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Myasthenia gravis
  • Phase II Chronic inflammatory demyelinating polyradiculoneuropathy; Cutaneous lupus erythematosus; Graves' disease; Rheumatoid arthritis
  • Phase I Autoimmune disorders
  • Preclinical Sjogren's syndrome

Most Recent Events

  • 29 May 2025 Roivant plans registrational trial for Graves' disease in the summer of 2025
  • 27 May 2025 Phase-III clinical trials in Myasthenia gravis in USA (SC) (NCT07039916)
  • 29 Apr 2025 Roivant Sciences initiates a pivotal trial in Graves' disease, prior to April 2025 (Roivant Sciences pipeline, April 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top